561297-87-8

Basic information

• Product Name: 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]
• Synonyms: 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]
• CAS NO: 561297-87-8
• Molecular Formula: C11H12N2O2
• Molecular Weight: 204.22518
• Mol File: 561297-87-8.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline](CAS DataBase Reference)
• NIST Chemistry Reference: 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline](561297-87-8)
• EPA Substance Registry System: 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline](561297-87-8)

Safety Data

• Hazardous Substances Data: 561297-87-8(Hazardous Substances Data)

Usage

General Description

7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline] is a chemical compound with the molecular formula C13H11N3O2. It is a spirocyclic compound containing a cyclopropane ring fused to an isoquinoline ring system. The compound is characterized by the presence of a nitro group at the 7' position and a dihydro group at the 2',3' positions of the spirocyclic ring. 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline] has potential applications in medicinal chemistry and drug development due to its unique structural features, which could impart specific biological activities. Further research and exploration of its properties may provide insights into its potential uses in pharmaceuticals or other fields.

Upstream product

• 18698-96-9 o-iodophenylacetic acid 
• 66370-75-0 methyl (2-iodophenyl)acetate 
• 1092794-08-5 1′H-spiro[cyclopropane-1,4’-isoquinoline]-3’(2’H)-one 
• 1092794-06-3 1-(2-cyanophenyl)cyclopropanecarboxylic acid methyl ester 
• 20921-96-4 methyl 2-(2-cyanophenyl)acetate 
• 18698-99-2 2-(2-cyanophenyl)acetic acid 
• 1092794-07-4 methyl 1-[2-(aminomethyl)phenyl]cyclopropanecarboxylate monohydrochloride 
• 1092794-09-6 7′-nitro-1’H-spiro [cyclopropane-1,4’-isoquinoline]-3’(2’H)-one 
• 618446-26-7 2,2,2-trifluoro-1-(7’-nitro-1‘H-spiro[cyclopropane-1,4’-isoquinolin]-2’(3‘H)-yl)ethan-1-one 

Downstream Products

• 1092793-92-4 3-(2,6-dichlorophenyl)-4-imino-7-[(2'-methyl-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one dihydrochloride 
• 561297-88-9 tert-butyl 7′-amino-1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′(3′H)-carboxylate 

Relevant articles and documents

Pyrrolopyrimidine compound, pharmaceutical composition containing thereof, and preparation method and applications

The invention relates to a pyrrolopyrimidine compound represented by formula I, a pharmaceutical composition containing thereof, and a preparation method and applications in preventing or treating Weel protein kinase related diseases.

Macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one and pharmaceutical composition and application thereof

The present invention relates to a macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one as shown in the formula (I) and/or a pharmaceutically acceptable salt thereof, and a composition of a compound of the formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method thereof, application thereof as a Wee1 inhibitor and application thereof as a sensitizer for cancer chemotherapy or radiotherapy. The macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and related signaling pathways, and has good cancer treatment and/or relieving effect.The formula is shown in the description.

COMPOSITIONS AND METHODS FOR TREATING CANCER

The instant invention relates to methods for the treatment of neuroblastoma by administering a combination of a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is WEE1-1 or a pharmaceutically acceptable salt thereof, or WEE1-2 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is CHK1-1 or a pharmaceutically acceptable salt thereof. In another embodiment, the invention relates to a method for treating a neuroblastoma patient, comprising administering a WEE1 inhibitor and a CHK1 inhibitor, wherein the cancer cells of said patient to be treated are characterized by amplified expression levels of MYCN.